IL106451A - Pharmaceutical preparations with reduced bitterness containing azithromycin - Google Patents

Pharmaceutical preparations with reduced bitterness containing azithromycin

Info

Publication number: IL106451A
Authority: IL; Israel
Prior art keywords: composition; azithromycin; composition according; taste; bitter
Prior art date: 1992-07-30

Application number

IL106451A

Other languages

English (en)

Hebrew (he)

Other versions

IL106451A0 (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-30

Filing date

1993-07-22

Publication date

1998-04-05

1993-07-22 Application filed by Pfizer filed Critical Pfizer

1993-11-15 Publication of IL106451A0 publication Critical patent/IL106451A0/xx

1998-04-05 Publication of IL106451A publication Critical patent/IL106451A/en

Links

235000019658 bitter taste Nutrition 0.000 title claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
229960004099 azithromycin Drugs 0.000 title claims description 35
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims description 35
229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims abstract description 5
239000003937 drug carrier Substances 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 88
150000003839 salts Chemical class 0.000 claims description 25
239000000796 flavoring agent Substances 0.000 claims description 23
235000019634 flavors Nutrition 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 21
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 17
239000000395 magnesium oxide Substances 0.000 claims description 15
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 13
238000000034 method Methods 0.000 claims description 11
239000004227 calcium gluconate Substances 0.000 claims description 8
229960004494 calcium gluconate Drugs 0.000 claims description 8
235000013927 calcium gluconate Nutrition 0.000 claims description 8
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 8
239000007910 chewable tablet Substances 0.000 claims description 7
239000006194 liquid suspension Substances 0.000 claims description 6
229940068682 chewable tablet Drugs 0.000 claims description 5
235000016623 Fragaria vesca Nutrition 0.000 claims description 4
240000009088 Fragaria x ananassa Species 0.000 claims description 4
235000011363 Fragaria x ananassa Nutrition 0.000 claims description 4
239000006071 cream Substances 0.000 claims description 4
235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
240000006365 Vitis vinifera Species 0.000 claims description 3
235000014787 Vitis vinifera Nutrition 0.000 claims description 3
239000012453 solvate Substances 0.000 claims description 3
241000167854 Bourreria succulenta Species 0.000 claims description 2
235000016795 Cola Nutrition 0.000 claims description 2
235000011824 Cola pachycarpa Nutrition 0.000 claims description 2
244000024873 Mentha crispa Species 0.000 claims description 2
235000014749 Mentha crispa Nutrition 0.000 claims description 2
244000290333 Vanilla fragrans Species 0.000 claims description 2
235000009499 Vanilla fragrans Nutrition 0.000 claims description 2
235000012036 Vanilla tahitensis Nutrition 0.000 claims description 2
235000020289 caffè mocha Nutrition 0.000 claims description 2
235000019693 cherries Nutrition 0.000 claims description 2
235000019219 chocolate Nutrition 0.000 claims description 2
239000008177 pharmaceutical agent Substances 0.000 abstract description 33
230000000694 effects Effects 0.000 abstract description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
239000003826 tablet Substances 0.000 description 19
150000007514 bases Chemical class 0.000 description 12
235000003599 food sweetener Nutrition 0.000 description 11
239000003765 sweetening agent Substances 0.000 description 11
239000000049 pigment Substances 0.000 description 9
-1 psuedoephedrine Chemical compound 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
239000001863 hydroxypropyl cellulose Substances 0.000 description 8
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000000725 suspension Substances 0.000 description 8
235000019636 bitter flavor Nutrition 0.000 description 7
238000005469 granulation Methods 0.000 description 7
230000003179 granulation Effects 0.000 description 7
VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 description 6
229960004924 azithromycin dihydrate Drugs 0.000 description 6
239000011230 binding agent Substances 0.000 description 6
239000006186 oral dosage form Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
108010011485 Aspartame Proteins 0.000 description 5
206010013911 Dysgeusia Diseases 0.000 description 5
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
239000000605 aspartame Substances 0.000 description 5
235000010357 aspartame Nutrition 0.000 description 5
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
229960003438 aspartame Drugs 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000004067 bulking agent Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000004014 plasticizer Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000019204 saccharin Nutrition 0.000 description 3
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
229940081974 saccharin Drugs 0.000 description 3
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
235000019640 taste Nutrition 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
235000021311 artificial sweeteners Nutrition 0.000 description 2
239000002585 base Substances 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000007958 cherry flavor Substances 0.000 description 2
230000001055 chewing effect Effects 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
229940043237 diethanolamine Drugs 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
229940012017 ethylenediamine Drugs 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000000174 gluconic acid Substances 0.000 description 2
235000012208 gluconic acid Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229960000869 magnesium oxide Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229960003194 meglumine Drugs 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
235000021096 natural sweeteners Nutrition 0.000 description 2
239000003605 opacifier Substances 0.000 description 2
235000019371 penicillin G benzathine Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229960000281 trometamol Drugs 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-MBMOQRBOSA-N D-mannonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-MBMOQRBOSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Chemical class 0.000 description 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229910017976 MgO 4 Inorganic materials 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Chemical class 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008122 artificial sweetener Substances 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
239000000292 calcium oxide Substances 0.000 description 1
ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
ZCZLQYAECBEUBH-UHFFFAOYSA-L calcium;octadec-9-enoate Chemical compound [Ca+2].CCCCCCCCC=CCCCCCCCC([O-])=O.CCCCCCCCC=CCCCCCCCC([O-])=O ZCZLQYAECBEUBH-UHFFFAOYSA-L 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
229930195406 erythrolide Natural products 0.000 description 1
LKHYFCSSVZVVNF-UHFFFAOYSA-N ethyl hexanoate;sodium Chemical compound [Na].CCCCCC(=O)OCC LKHYFCSSVZVVNF-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Chemical class 0.000 description 1
239000008273 gelatin Chemical class 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
235000015243 ice cream Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
229960001571 loperamide Drugs 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
230000011514 reflex Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Chemical class 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
210000001779 taste bud Anatomy 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

IL106451A 1992-07-30 1993-07-22 Pharmaceutical preparations with reduced bitterness containing azithromycin IL106451A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92226292A	1992-07-30	1992-07-30

Publications (2)

Publication Number	Publication Date
IL106451A0 IL106451A0 (en)	1993-11-15
IL106451A true IL106451A (en)	1998-04-05

Family

ID=25446788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL106451A IL106451A (en)	1992-07-30	1993-07-22	Pharmaceutical preparations with reduced bitterness containing azithromycin

Country Status (29)

Country	Link
US (1)	US5633006A (ja)
EP (1)	EP0582396B1 (ja)
JP (1)	JP2685403B2 (ja)
KR (1)	KR100242399B1 (ja)
CN (1)	CN1030964C (ja)
AT (1)	ATE198421T1 (ja)
AU (1)	AU655892B2 (ja)
CA (1)	CA2101466C (ja)
CZ (1)	CZ285057B6 (ja)
DE (1)	DE69329810T2 (ja)
DK (1)	DK0582396T3 (ja)
EG (1)	EG20385A (ja)
ES (1)	ES2153836T3 (ja)
FI (1)	FI933404L (ja)
GR (1)	GR3035426T3 (ja)
HR (1)	HRP931049B1 (ja)
HU (1)	HU221682B1 (ja)
IL (1)	IL106451A (ja)
MX (1)	MX9304577A (ja)
MY (1)	MY110581A (ja)
NO (1)	NO308023B1 (ja)
NZ (1)	NZ248280A (ja)
PL (1)	PL174795B1 (ja)
PT (1)	PT582396E (ja)
RU (1)	RU2126257C1 (ja)
SK (1)	SK280194B6 (ja)
TW (1)	TW271400B (ja)
YU (1)	YU52593A (ja)
ZA (1)	ZA935475B (ja)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
AU680356B2 (en) *	1994-05-06	1997-07-24	Pfizer Inc.	Controlled-release dosage forms of azithromycin
JP3610418B2 (ja) *	1995-08-08	2005-01-12	カシオ計算機株式会社	液晶駆動方法及び液晶表示装置
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6551616B1 (en) *	1997-04-11	2003-04-22	Abbott Laboratories	Extended release formulations of erythromycin derivatives
US20050064033A1 (en) *	1997-04-11	2005-03-24	Notario Gerard F.	Extended release formulations of erythromycin derivatives
GB9725219D0 (en) *	1997-11-29	1998-01-28	Cleansharp Ltd	Tablets
EP1163852A4 (en) *	1999-02-18	2002-06-12	Fujisawa Pharmaceutical Co	Masking agent
US6239141B1 (en)	1999-06-04	2001-05-29	Pfizer Inc.	Trovafloxacin oral suspensions
FR2795962B1 (fr) *	1999-07-08	2003-05-09	Prographarm Laboratoires	Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6565882B2 (en)	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020068078A1 (en)	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
EP1671979B1 (en)	2001-05-22	2008-08-13	Pfizer Products Inc.	New Cristal Form of Azithromycin
ES2323264T3 (es) *	2001-08-01	2009-07-10	Novartis Ag	Composicion para enmascaramiento del sabor.
MXPA04001605A (es) *	2001-08-21	2004-07-08	Pfizer Prod Inc	Azitromicina en una sola dosis para tratar infecciones respiratorias.
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US8900498B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en)	2001-10-12	2007-12-06	Fuisz Richard C	Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en)	2001-10-12	2019-10-31	Aquestive Therapeutics, Inc.	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en)	2009-08-07	2011-02-10	Monosol Rx, Llc	Sublingual and buccal film compositions
US11207805B2 (en)	2001-10-12	2021-12-28	Aquestive Therapeutics, Inc.	Process for manufacturing a resulting pharmaceutical film
US10285910B2 (en)	2001-10-12	2019-05-14	Aquestive Therapeutics, Inc.	Sublingual and buccal film compositions
US7357891B2 (en)	2001-10-12	2008-04-15	Monosol Rx, Llc	Process for making an ingestible film
US8900497B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for making a film having a substantially uniform distribution of components
US8603514B2 (en)	2002-04-11	2013-12-10	Monosol Rx, Llc	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en)	2001-10-12	2014-07-01	Monosol Rx, Llc	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
EP1541134A3 (en) *	2001-10-18	2007-06-06	Teva Pharmaceutical Industries Limited	Stabilized azithromycin compositions
CA2469246A1 (en) *	2001-12-21	2003-07-03	Pfizer Products Inc.	Directly compressible formulations of azithromycin
AU2002353316A1 (en) *	2001-12-21	2003-07-09	Pfizer Products Inc.	Methods for wet granulating azithromycin
NZ534234A (en) *	2002-02-01	2007-05-31	Pfizer Prod Inc	Dry granulated formulations of non-dihydrate form of azithromycin
EP2446889A1 (en) *	2002-04-26	2012-05-02	Fancl Corporation	Difructose anhydride-containing composition for use in improving bowel movement
US20040170686A1 (en) *	2003-01-31	2004-09-02	Fredrickson Jennifer K.	Suspension vehicle for coated drug particles
US20040191326A1 (en) *	2003-03-31	2004-09-30	Reo Joseph P.	Taste-masking vehicle for coated oxazolidinone particles
CN1744881A (zh) *	2003-04-02	2006-03-08	普利瓦研究与发展有限公司	苦味减轻了的药物组合物
KR100503949B1 (ko) *	2003-04-28	2005-07-26	주식회사유한양행	염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
WO2005002592A2 (en) *	2003-07-01	2005-01-13	Ranbaxy Laboratories Limited	Stable oral compositions of azithromycin monohydrate
US20050013835A1 (en) *	2003-07-15	2005-01-20	Pfizer Inc.	Stable non-dihydrate azithromycin oral suspensions
US8313776B2 (en)	2003-07-21	2012-11-20	Shionogi Inc.	Antibiotic product, use and formulation thereof
WO2005009364A2 (en)	2003-07-21	2005-02-03	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
CA2533292C (en)	2003-07-21	2013-12-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
EP1653925A1 (en)	2003-08-11	2006-05-10	Advancis Pharmaceutical Corporation	Robust pellet
US8062672B2 (en)	2003-08-12	2011-11-22	Shionogi Inc.	Antibiotic product, use and formulation thereof
WO2005023184A2 (en)	2003-08-29	2005-03-17	Advancis Pharmaceuticals Corporation	Antibiotic product, use and formulation thereof
AU2004273830B2 (en)	2003-09-15	2011-03-24	Shionogi, Inc.	Antibiotic product, use and formulation thereof
US8168228B2 (en) *	2003-10-17	2012-05-01	Sandoz Ag	Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) *	2003-10-17	2005-04-21	Indranil Nandi	Taste masking antibiotic composition
US20050101547A1 (en) *	2003-11-06	2005-05-12	Sadatrezaei Mohsen	Stabilized azithromycin composition
BRPI0417348A (pt)	2003-12-04	2007-03-13	Pfizer Prod Inc	processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
JP2007513143A (ja) *	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
EP1691786A1 (en)	2003-12-04	2006-08-23	Pfizer Products Inc.	Multiparticulate compositions with improved stability
AP2218A (en) *	2003-12-04	2011-04-20	Pfizer Prod Inc	Azithromycin dosage forms with reduced side effects
US6984403B2 (en) *	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en)	2003-12-04	2005-06-16	Pfizer Products Inc.	Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547774A1 (en)	2003-12-04	2005-06-16	Pfizer Products Inc.	Method for making pharmaceutical multiparticulates
RU2006119453A (ru) *	2003-12-04	2007-12-20	Пфайзер Продактс Инк. (Us)	Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
WO2005053639A2 (en) *	2003-12-04	2005-06-16	Pfizer Products Inc.	Controlled release multiparticulates formed with dissolution enhancers
CA2572292A1 (en)	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
US20060024335A1 (en) *	2004-07-29	2006-02-02	Roger Stier E	Oral compositions which mask the bitter taste of a bitter-tasting agent
JP2006052169A (ja) *	2004-08-12	2006-02-23	Wakoudou Kk	ゾル状又はゲル状の服薬補助食品
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
US20060105039A1 (en)	2004-10-21	2006-05-18	Jin-Wang Lai	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
KR20070104884A (ko)	2004-11-24	2007-10-29	메드포인트 헬쓰케어 인크.	아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US20070020330A1 (en)	2004-11-24	2007-01-25	Medpointe Healthcare Inc.	Compositions comprising azelastine and methods of use thereof
US20060198885A1 (en) *	2005-02-22	2006-09-07	Sun Pharmaceutical Industries Ltd.	Oral pharmaceutical composition
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
AU2016202290B2 (en) *	2005-06-17	2017-10-05	Wisconsin Alumni Research Foundation	Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
US9101160B2 (en)	2005-11-23	2015-08-11	The Coca-Cola Company	Condiments with high-potency sweetener
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en)	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
JP4963846B2 (ja) *	2006-03-03	2012-06-27	エルメッドエーザイ株式会社	口腔内崩壊錠及びその製造方法
ATE486593T1 (de) *	2006-03-16	2010-11-15	Novartis Ag	Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
US8017168B2 (en)	2006-11-02	2011-09-13	The Coca-Cola Company	High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
EP2030644A1 (en) *	2007-08-31	2009-03-04	PARI Pharma GmbH	Aerosols for sinunasal drug delivery
CN105732745A (zh)	2007-10-25	2016-07-06	森普拉制药公司	大环内酯类抗菌剂的制备方法
TWI468167B (zh)	2007-11-16	2015-01-11	威佛（國際）股份有限公司	藥學組成物
BRPI0906648A2 (pt) *	2008-01-31	2019-11-19	Mcneil Ppc Inc	tiras de filme comestível para liberação imediata de ingredientes ativos
EP2098219A1 (en)	2008-03-05	2009-09-09	PARI Pharma GmbH	Macrolide compositions having improved taste and stability
US20100297232A1 (en) *	2009-05-19	2010-11-25	Monosol Rx, Llc	Ondansetron film compositions
NZ600256A (en)	2009-12-02	2014-05-30	Aptalis Pharma Ltd	Fexofenadine microcapsules and compositions containing them
WO2012029913A1 (ja) *	2010-09-01	2012-03-08	興和株式会社	経口剤
US9149959B2 (en)	2010-10-22	2015-10-06	Monosol Rx, Llc	Manufacturing of small film strips
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
IN2014MN01706A (ja) *	2012-02-28	2015-05-29	Seoul Pharma Co Ltd
IN2014DN08939A (ja)	2012-03-27	2015-05-22	Cempra Pharmaceuticals Inc
RU2498805C1 (ru) *	2012-07-23	2013-11-20	Открытое акционерное общество "Биосинтез"	Твердая лекарственная форма азитромицина
CN103961368B (zh) *	2013-12-05	2017-01-04	广西大学	蒙脱石负载的氢氧化钙抗酸剂
RS63559B1 (sr)	2014-08-28	2022-10-31	Eisai R&D Man Co Ltd	Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
PL3263106T3 (pl)	2015-02-25	2024-04-02	Eisai R&D Management Co., Ltd.	Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
RU2729936C2 (ru)	2015-06-16	2020-08-13	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противораковое средство
RU2718048C2 (ru)	2015-08-20	2020-03-30	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое терапевтическое средство
US11273131B2 (en)	2016-05-05	2022-03-15	Aquestive Therapeutics, Inc.	Pharmaceutical compositions with enhanced permeation
CN109310646A (zh)	2016-05-05	2019-02-05	阿奎斯蒂弗医疗股份有限公司	增强递送的肾上腺素组合物
KR20200013644A (ko)	2017-05-16	2020-02-07	에자이 알앤드디 매니지먼트 가부시키가이샤	간세포 암종의 치료
HUE062682T2 (hu) *	2018-11-16	2023-11-28	Ssp Co Ltd	Ibuprofén tartalmú orális gyógyszerészeti készítmény
EP3973030A4 (en) *	2019-05-23	2023-05-31	Ekyj Consulting II, LLC	COMPOSITIONS AND METHODS FOR THE TREATMENT AND ALLEVIATION OF ALCOHOL-INDUCED SKIN REDNESS
WO2022139863A1 (en) *	2020-12-22	2022-06-30	Solugen, Inc.	Bitter masking agent

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3627885A (en) *	1968-07-18	1971-12-14	Rit Rech Ind Therapeut	Stabilized antibiotic compositions for animal feeding
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4678661A (en) *	1983-09-28	1987-07-07	Gerhard Gergely	Effervescent composition and method of making same
US4761274A (en) *	1986-03-27	1988-08-02	Warner-Lambert Company	Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
US4800087A (en) *	1986-11-24	1989-01-24	Mehta Atul M	Taste-masked pharmaceutical compositions
WO1989002271A1 (en) *	1987-09-10	1989-03-23	Pfizer	Azithromycin and derivatives as antiprotozoal agents
JP2831004B2 (ja) *	1988-09-29	1998-12-02	大日本製薬株式会社	粉粒状医薬製剤
YU45590A (sh) *	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
ZA922777B (en) *	1991-04-29	1993-10-15	Lilly Co Eli	Pharmaceutical formulation containing dirithromycin
IT1250701B (it) *	1991-07-24	1995-04-21	Angelini Francesco Ist Ricerca	Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH05139996A (ja) *	1991-11-15	1993-06-08	Lion Corp	苦味が軽減された鎮咳去痰製剤用組成物
IL104093A (en) *	1991-12-31	1999-06-20	Abbott Lab	Prolamine is expected to mask the taste of drugs given orally
JPH05255120A (ja) *	1992-03-12	1993-10-05	Taisho Pharmaceut Co Ltd	苦み隠蔽製剤
DE4216756C2 (de) *	1992-05-21	1994-08-25	Pharmatrans Sanaq Ag	2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
GB9211148D0 (en) *	1992-05-26	1992-07-08	Smithkline Beecham Plc	Novel treatment

1993
- 1993-06-08 TW TW082104534A patent/TW271400B/zh active
- 1993-07-14 HR HR931049A patent/HRP931049B1/xx not_active IP Right Cessation
- 1993-07-14 PT PT93305515T patent/PT582396E/pt unknown
- 1993-07-14 EP EP93305515A patent/EP0582396B1/en not_active Expired - Lifetime
- 1993-07-14 DE DE69329810T patent/DE69329810T2/de not_active Expired - Fee Related
- 1993-07-14 AT AT93305515T patent/ATE198421T1/de not_active IP Right Cessation
- 1993-07-14 DK DK93305515T patent/DK0582396T3/da active
- 1993-07-14 ES ES93305515T patent/ES2153836T3/es not_active Expired - Lifetime
- 1993-07-22 IL IL106451A patent/IL106451A/en not_active IP Right Cessation
- 1993-07-26 JP JP5183954A patent/JP2685403B2/ja not_active Expired - Fee Related
- 1993-07-27 CZ CZ931518A patent/CZ285057B6/cs not_active IP Right Cessation
- 1993-07-28 CA CA002101466A patent/CA2101466C/en not_active Expired - Fee Related
- 1993-07-28 MY MYPI93001485A patent/MY110581A/en unknown
- 1993-07-28 AU AU44261/93A patent/AU655892B2/en not_active Ceased
- 1993-07-28 EG EG47993A patent/EG20385A/xx active
- 1993-07-29 HU HU9302213A patent/HU221682B1/hu not_active IP Right Cessation
- 1993-07-29 NO NO932736A patent/NO308023B1/no unknown
- 1993-07-29 KR KR1019930014564A patent/KR100242399B1/ko not_active Expired - Fee Related
- 1993-07-29 PL PL93299865A patent/PL174795B1/pl not_active IP Right Cessation
- 1993-07-29 RU RU93042471A patent/RU2126257C1/ru not_active IP Right Cessation
- 1993-07-29 FI FI933404A patent/FI933404L/fi unknown
- 1993-07-29 MX MX9304577A patent/MX9304577A/es not_active IP Right Cessation
- 1993-07-29 CN CN93109317A patent/CN1030964C/zh not_active Expired - Fee Related
- 1993-07-29 ZA ZA935475A patent/ZA935475B/xx unknown
- 1993-07-29 NZ NZ248280A patent/NZ248280A/en not_active IP Right Cessation
- 1993-07-30 YU YU52593A patent/YU52593A/sh unknown
- 1993-07-30 SK SK821-93A patent/SK280194B6/sk unknown
1994
- 1994-10-24 US US08/328,977 patent/US5633006A/en not_active Expired - Fee Related
2001
- 2001-02-14 GR GR20010400257T patent/GR3035426T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
MX9304577A (es)	1994-02-28
AU655892B2 (en)	1995-01-12
EP0582396A1 (en)	1994-02-09
RU2126257C1 (ru)	1999-02-20
AU4426193A (en)	1994-04-28
CN1083728A (zh)	1994-03-16
HU221682B1 (hu)	2002-12-28
HUT64692A (en)	1994-02-28
IL106451A0 (en)	1993-11-15
HU9302213D0 (en)	1993-10-28
HRP931049A2 (en)	1997-08-31
US5633006A (en)	1997-05-27
ATE198421T1 (de)	2001-01-15
FI933404L (fi)	1994-01-31
PL174795B1 (pl)	1998-09-30
MY110581A (en)	1998-08-29
HRP931049B1 (en)	2001-06-30
DE69329810T2 (de)	2001-06-21
NZ248280A (en)	1995-07-26
FI933404A0 (fi)	1993-07-29
CN1030964C (zh)	1996-02-14
YU52593A (sh)	1996-05-20
EG20385A (en)	1999-02-28
DE69329810D1 (de)	2001-02-08
ES2153836T3 (es)	2001-03-16
PL299865A1 (en)	1994-02-07
SK82193A3 (en)	1994-02-02
CA2101466C (en)	2000-06-06
GR3035426T3 (en)	2001-05-31
JPH06206824A (ja)	1994-07-26
PT582396E (pt)	2001-04-30
TW271400B (ja)	1996-03-01
DK0582396T3 (da)	2001-04-09
SK280194B6 (sk)	1999-09-10
CZ285057B6 (cs)	1999-05-12
CA2101466A1 (en)	1994-01-31
KR940001902A (ko)	1994-02-16
NO308023B1 (no)	2000-07-10
CZ151893A3 (en)	1994-03-16
NO932736L (no)	1994-01-31
KR100242399B1 (ko)	2000-03-02
ZA935475B (en)	1995-01-29
NO932736D0 (no)	1993-07-29
EP0582396B1 (en)	2001-01-03
JP2685403B2 (ja)	1997-12-03

Publication	Publication Date	Title
EP0582396B1 (en)	2001-01-03	Taste-masking composition of bitter pharmaceutical agents
US4716033A (en)	1987-12-29	Medicament adsorbates with surfactant and their preparation
EP0396335B1 (en)	1994-02-02	Pharmaceutical formulation
US4761274A (en)	1988-08-02	Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
EP0239542B1 (en)	1991-04-10	Medicament adsorbates with complex magnesium aluminum silicate and their preparation
CA2408198C (en)	2004-03-09	Pharmaceutical composition comprising cefuroxime axetil
EP1166801A1 (en)	2002-01-02	Preparations containing silicon dioxide to improve the taste thereof
KR20020029668A (ko)	2002-04-19	풍미 차단된 약제학적 액상 제제
JP2006514968A (ja)	2006-05-18	低減された苦味を有する製薬組成物
KR20040099403A (ko)	2004-11-26	저 투여량의 액체 엔테카비르 제제 및 용도
US6930119B2 (en)	2005-08-16	Liquid pharmaceutical composition
US20070286901A1 (en)	2007-12-13	Novel Pharmaceutical Formulation of Cefixime for Enhanced Bioavailability
WO2001085134A1 (en)	2001-11-15	Pharmaceutical solid compositions and process for the production of mouth dissolving tablets
WO2000023046A1 (en)	2000-04-27	Chewable or dissolvable pharmaceutical compositions suitable for oral administration

Legal Events

Date	Code	Title
1998-10-30	FF	Patent granted
1998-12-27	KB	Patent renewed
1999-12-22	KB	Patent renewed
2003-09-17	KB	Patent renewed
2007-08-19	KB	Patent renewed
2012-02-29	MM9K	Patent not in force due to non-payment of renewal fees